Evidence map›Paper›PMID 30962427›Full record

ReviewCell death & disease2019

Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care.

Anna Tarocco, Natascia Caroccia, Giampaolo Morciano, Mariusz R Wieckowski, Gina Ancora, Giampaolo Garani, Paolo Pinton

Open access · goldAbstract readReview
In one paragraph

Review in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 4 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 4 syntheses or guidelines pooled it, 285 citations in OpenAlex.

  1. Melatonin treatment for neonatal encephalopathy.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. The Effect of Melatonin on Periodontitis.International journal of molecular sciences · 2021
    Trial
  7. Antioxidant Effect of Melatonin in Preterm Newborns.Oxidative medicine and cellular longevity · 2021
    Trial
  8. Review
  9. Melatonin exerts anOncology letters · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Anna TaroccoDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. anna.tarocco@unife.it.
Natascia CarocciaDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
Giampaolo MorcianoDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
Mariusz R WieckowskiDepartment of Biochemistry, Nencki Institute of Experimental biology, 02-093, Warsaw, Poland.
Gina AncoraNeonatal Intensive Care Unit, Infermi Hospital Rimini, Rimini, Italy.
Giampaolo GaraniNeonatal Intensive Care Unit, University Hospital S. Anna Ferrara, Ferrara, Italy.
Paolo PintonDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. paolo.pinton@unife.it.ORCID http://orcid.org/0000-0001-7108-6508
University of Ferrara · ITInstytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLOspedale Infermi di Rimini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melatonin, more commonly known as the sleep hormone, is mainly secreted by the pineal gland in dark conditions and regulates the circadian rhythm of the organism. Its intrinsic properties, including high cell permeability, the ability to easily cross both the blood-brain and placenta barriers, and its role as an endogenous reservoir of free radical scavengers (with indirect extra activities), confer it beneficial uses as an adjuvant in the biomedical field. Melatonin can exert its effects by acting through specific cellular receptors on the plasma membrane, similar to other hormones, or through receptor-independent mechanisms that involve complex molecular cross talk with other players. There is increasing evidence regarding the extraordinary beneficial effects of melatonin, also via exogenous administration. Here, we summarize molecular pathways in which melatonin is considered a master regulator, with attention to cell death and inflammation mechanisms from basic, translational and clinical points of view in the context of newborn care.

Indexed as

AutophagyBlood-Brain BarrierCell DeathFemaleFree Radical ScavengersHumansInfant, NewbornInfant, Newborn, DiseasesInflammationMelatoninMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PorePlacentaPregnancyPremature BirthReceptors, MelatoninFree Radical ScavengersMelatoninMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreReceptors, Melatonin

Identifiers

PMID30962427
PMCPMC6453953
OpenAlexW2926178629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.